 |
|
|
 |
|
|
     |
 |
 |
 |
 |
|
This study on uterine bleeding was presented during the ACOG meeting that took place in San Diego, USA, in June, 2007. In this study Gordon et al. compared iron carboxymaltose to oral iron therapy for the treatment of iron deficiency anemia associated with heavy uterine bleeding. Iron deficiency anaemia secondary to heavy uterine bleeding or the postpartum state develops very gradually and virtually unnoticed, with quality of life deficits comparable to chronic illnesses. |
|
|
Date Published: 06/2007
Iron Carboxymaltose, A New Intravenous Iron Agent for Iron Deficiency in Heavy Uterine Bleeding
Gordon S, Hadley PE, Van Wyck DB, Mangione A
Obstet Gynecol 2007 Apr;109(4 Suppl):1S-127S. PubMed
 
During the ACOG meeting that took place in San Diego, USA, in May, Gordon et al. presented a study that compared iron carboxymaltose to oral iron therapy for the treatment of iron deficiency anemia associated with heavy uterine bleeding.
The authors found iron carboxymaltose to be superior to oral iron in correcting anemia, replenishing iron stores, and improving quality of life. |
|
| Links to related articles |
ITO Editorial Staff
James AH, Ragni MV, Picozzi VJ |
|
This study, presented at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, Gordon et al presented a study that examined the efficacy of a new intravenous iron agent, iron carboxymaltose, in treating iron deficiency anemia in 228 women with heavy uterine bleeding.
Patients receiving iron carboxymaltose (1000 mg or less, administered over 15 minutes, once a week) were more likely to achieve a 2 g/dL rise in hemoglobin concentration (Hb) (82% vs. 62%, p < 0.001) compared to oral iron (325 mg [65 mg elemental iron] three times daily for 6 weeks). An improvement in analog fatigue scales and SF-36 quality of life scores was also shown (p < 0.05 at day 14 and later).
The authors conclude that iron carboxymaltose is superior to oral iron in treating iron deficiency due to heavy uterine bleeding.
|
|
|
|
|
|
|
 |
